Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$41.05 USD

41.05
2,741,662

+0.36 (0.88%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $41.06 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Feb 25, 2022

by Zacks Equity Research

Companies in The News Are: AEP,ATHM,IONS,DISH

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis

by Zacks Equity Research

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Zacks Equity Research

Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.

Zacks Equity Research

Ionis' (IONS) Partner to Begin New Huntington's Disease Study

by Zacks Equity Research

Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

Zacks Equity Research

AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate

by Zacks Equity Research

AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.

Zacks Equity Research

Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis

by Zacks Equity Research

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

Zacks Equity Research

AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis

by Zacks Equity Research

AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.

Zacks Equity Research

Ionis (IONS) Collaborates With AstraZeneca for Eplontersen

by Zacks Equity Research

Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Down 24.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -9.43% and -16.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study

by Zacks Equity Research

Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.

Zacks Equity Research

Roche's (RHHBY) Sparks Set to Develop Gene Therapy for HD

by Zacks Equity Research

Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Up 3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1.79% and -9.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Zacks Equity Research

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

by Zacks Equity Research

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Zacks Equity Research

New Strong Sell Stocks for July 8th

by Zacks Equity Research

CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021

Zacks Equity Research

Why Is Ionis Pharmaceuticals (IONS) Down 7% Since Last Earnings Report?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

by Zacks Equity Research

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.